^
    Back
    Association details:
    Biomarker:MYC expression + BCL2 expression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Brukinsa (zanubrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    Retrospective Analysis of Clinical Outcomes of Utilizing R-CHOP Plus Zanubrutinib for High-Risk Diffuse Large B Cell Lymphoma Patients with Extranodal Involvement or MYC/BCL2 Double Expression

    Published date:
    11/02/2023
    Excerpt:
    The combination of 4 cycles of R-CHOP regimen with zanubrutinib in the induction treatment of DLBCL patients with high-risk factors, such as extranodal involvement or MYC/BCL2 double expression, has shown promising clinical outcomes especially in older or unfit/frail patients.
    Secondary therapy:
    R-CHOP
    DOI:
    https://doi.org/10.1182/blood-2023-182704